Alkermes

ALKS

Market cap $4.88B

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT) Piper Sandler 37th Annual Healthcare Conference Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alke.

Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.

Top-ranked stocks TakeTwo Interactive Software (TTWO), Allstate (ALL), SoFi Technologies (SOFI), Alkermes (ALKS) and Morgan Stanley (MS) are likely to beat on the bottom line in their upcoming releases.

Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's unexpected pitch.

Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final U.S. Food and Drug Administration ("FDA") LUMRYZ™ Approval (as defined in the form of CVR agreement to be entered into by Alkermes and the rights agent) for the treatment of idiopathic hypersomnia in adults by the end of 2028 (the "Increased Offer"). In connection with the Increased Offer, Alkermes and Avadel have entered into an amendment, dated November 18, 2025 (the "Amendment"), to the definitive transaction agreement between the parties (the "Transaction Agreement" and, as amended, the "Amended Agreement") previously entered into and announced on October 22, 2025 (the "October 2.7 Announcement").

Alkermes plc ( ALKS ) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luke Herrmann - Robert W.

Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.

The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.